A Study of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market by Drugs and Devices
Rising Number of Patients with Prostate Problems Propagating Progress of Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market. An In-depth Look at the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market with Special Focus on the United States, Canada, the United Kingdom, France, and Italy
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Outlook for 2024 to 2034
The benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to be worth US$ 33,031.10 million in 2024. The market is expected to grow at a steady rate over the period from 2024 to 2034, with a CAGR of 3.6%. By the end of the forecast period, the market value is predicted to hit US$ 47,045.80 million.
Attributes
Details
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Value for 2024
US$ 33,031.10 million
Projected Market Value for 2034
US$ 47,045.80 million
Value-based CAGR of Market for 2024 to 2034
3.6%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising number of people suffering from benign prostatic hyperplasia and prostate problems in general is informing the growth in demand for the treatment.
With growing preference towards minimally invasive surgeries, the demand for treatment procedures like transurethral needle ablation (TUNA) and prostatic urethral lift (PUL) is increasing.
Increasing reputation of prostate artery embolization (PAE), due to its positive results, is helping the market’s growth.
Innovations such as Optilume drug-coated balloon in benign prostatic hyperplasia (BPH) prostate treatment are aiding in the development of the market.
Rise in the geriatric population is leading to an increase in patients with benign prostatic hyperplasia, expanding the scope of the market.
Trends in BPH Prostate Treatment Market
Development of irregular eating habits due to the busy lifestyles of the youth is leading to an increase in BPH problems, necessitating the use of benign prostatic hyperplasia (BPH) prostate treatment.
Increasing number of patients are opting for homeopathy and natural remedies for BPH and thus the market has multiple avenues for growth.
Initiatives taken by governments to advance the healthcare system in their countries are creating a conducive environment for the market’s progress.
Alpha blockers remain popular as a form of treatment for BPH and the continuing demand for the drugs is benefitting the market.
Risk of side effects such as urinary tract infections and kidney damage limit the prospects of the market.
High cost of BPH prostate treatment, especially those using devices, is set to hinder the growth of the market.
Scientific skepticism over BPH home remedies and homeopathy solutions is set to restrict the growth of the market through those avenues.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of Adjacent Markets
Aside from the benign prostatic hyperplasia (BPH) prostate treatment market, analysis has been done on two other related markets. The markets by name are the prostate health market and the prostate cancer market.
Consumers becoming more knowledgeable about prostate health is driving the prostate health market. Development in health infrastructure is also aiding the prostate health market’s growth.
Development of new oral therapies like darolutamide (Nubeqa), and enzalutamide (Xtandi) is increasing the success rate of prostate cancer treatments. Government initiatives to raise awareness about prostate cancer are also benefitting the market.
Consumer inclination towards minimally invasive procedures
Restraint
Rising costs of BPH treatment
Growth Factors
Rising number of people diagnosed with BPH
Growing popularity of prostate artery embolization (PAE)
Prostate Health Market:
Attributes
Prostate Health Market
Value-based CAGR (2024 to 2034)
9.2%
Market Trend
Increase in public and private sector funding for prostate-related research
Restraint
Disdain towards side effects caused by prostate health treatments
Growth Factor
Rise in geriatric population
Prostate Cancer Market:
Attributes
Prostate Cancer Market
Value-based CAGR (2024 to 2034)
8.5%
Market Trend
Use of AI tools to manage prostate cancer treatments
Restraint
Lack of skilled personnel to operate machinery used in prostate cancer treatments
Growth Factors
Betterment of health infrastructure in developing nations
Category-wise Outlook
Drugs continue to be the preferred treatment type for BPH. Institutional sales top the distribution channel segment.
Easy Administering Capabilities and Development of New Products Make Sure Drugs Remain the Predominant Treatment Type
For 2024, drugs are expected to account for 65.2% of the market share by treatment type. Some of the key drivers for the increasing use of drugs in BPH treatment are:
Easy administration of drugs makes them popular as forms of treatment in the wider healthcare sector and that popularity is reflected in the benign prostatic hyperplasia (BPH) prostate treatment market.
Development of drugs like tadalafil for BPH treatment, previously used exclusively to treat erectile dysfunction, is helping drugs to infiltrate further in the treatment of patients.
Attributes
Details
Top Treatment Type
Drugs
Market Share (2024)
65.2%
Increase in Research Related to Prostate-related Problems is Seeing Institutional Sales Grow
Institutional sales are anticipated to account for 64.7% of the market share in 2024. Some of the key drivers for the progress of institutional sales include:
Research institutes are receiving funding from both the private and public sectors in an increasing manner. Thus, their buying capacity is increasing, and institutional sales of BPH treatment are growing.
Proliferation of specialty clinics trading in minimally invasive surgeries is benefitting the development of institutional sales of BPH treatment.
Attributes
Details
Top Distribution Channel
Institutional Sales
Market Share (2024)
64.7%
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Analysis
The increasing geriatric population is contributing to the market’s acceleration in North America. The presence of a wide variety of treatments is also propelling the benign prostatic hyperplasia (BPH) prostate treatment industry in North America.
Advancement of research institutions is lending a helping hand to the progress of the market in the region. The focus on the technological development of healthcare companies in the region is making sure BPH treatment keeps up with the times in Europe.
Countries
CAGR
United States
4.0%
Canada
3.1%
United Kingdom
3.7%
France
3.3%
Italy
3.5%
Approval of New Treatment Methods Keeping Market Demand Flowing in the United States
The market is set to register a CAGR of 4.0% in the United States for the forecast period. The key drivers for growth are:
Innovative treatment procedures for benign prostatic hyperplasia, such as the Optilume BPH catheter system, getting approvals at a faster rate is seeing the market develop positively in the United States.
Transurethral resection of the prostate (TURP) remains ever-popular in the United States and thus the market is enjoying normal growth in the country.
Technological Advancement Informing Growth of the Market in Canada
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in Canada is tipped to be 3.1% over the forecast period. Some of the key factors driving the growth are:
Canadian companies are increasingly taking the help of technology and making the newest treatment forms available to consumers. Thus, the market is in for growth in the country.
Irregular eating habits of a significant portion of Canadian consumers are leading to increased development of BPH patients in the country. Thus, BPH treatments are being sought in increasing measure in Canada.
Constant Innovation Through Research Affects Market Positively in the United Kingdom
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in the United Kingdom is tipped to be 3.7% over the forecast period. Some of the key factors driving the growth are:
Research regarding BPH is being encouraged in the United Kingdom and the market is benefitting as a result. For example, in November 2023, the transurethral water-jet ablation treatment was made available country-wide in the United Kingdom after limited trials of five years.
In January 2024, King Charles of the United Kingdom was affected by and underwent surgery for benign prostatic hyperplasia, raising the profile of BPH treatment in the country.
Governmental Concessions for BPH Treatment Sees the Market Enlarge in France
The market is expected to register a CAGR of 3.3% in France for the forecast period. Some of the key trends include:
France’s government has taken steps to lower the cost of BPH treatment, which is helping the market’s cause in the country. For example, in March 2021, the Urolift implant procedure, courtesy of Teleflex Incorporated, was made reimbursable to patients above 50 years of age in France.
Growing popularity of minimally invasive procedures in France sees BPH treatment of the minimally invasive nature progress in the country.
Development of New Supplements Freshening Up the Demand for BPH Treatment in Italy
The market is expected to register a CAGR of 3.5% in Italy over the forecast period. Some of the key trends include:
Designing new supplements is aiding the market’s cause in Italy. For example, in 2021, trials found a whole tomato based food supplement eased the pain of men afflicted with benign prostatic hyperplasia in Italy.
Rapidly aging population of Italy is developing prostate disorders at a greater rate and thus BPH treatment demand is increasing in the country.
Competitive Landscape in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
The benign prostatic hyperplasia (BPH) prostate treatment market is competitive, though a few companies are prominent in the market. One of the well-established companies in the market is Pfizer Inc., who are concentrated on expansion through its alpha-blockers range.
Other players in the market are implementing strategies such as acquisitions and mergers to get a competitive edge. Research and development are also given importance by these market players.
Recent Developments in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
In May 2023, the English football club Sutton United was sponsored by Ideal Medical Solutions Ltd. The sponsorship aimed to raise awareness of the Elesta Echo-Laser treatment device for BPH.
In February 2023, it was announced that the New Hall Hospital in Bodenham, England will receive equipment for the new ablation treatment procedure of BPH. The treatment uses imaging, robotics, and a heat-free water jet.
In June 2022, the first BPH treatment with the iTind device was done in Canada by Olympus.
Key Companies in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
Pfizer Inc.
NxThera Inc.
NeoTract Inc.
Sanofi S.A
GlaxoSmithKline Plc.
Allergan Plc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Eli Lily & Company
Cardinal Health Inc.
Key Coverage in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry Report
Emerging trends in surgical BPH treatment analysis
Key Segments
By Treatment Type:
BPH Drugs
Alpha Blockers
5-Alpha Reductase Inhibitors
Phosphodiesterase-5 (PDE-5) Inhibitors
Muscarinic Receptor Antagonist (MRA)
Combination Drug
BPH Devices
Prostatic Stents
Suture Base Implant Systems
Transurethral RF Thermal Therapy Devices
By Distribution Channel:
Institutional Sales
Hospitals
Ambulatory Surgical Centres
Specialty Clinics
Retail Sales
Retail Pharmacies
Drug Stores
Online Pharmacies
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)
Frequently Asked Questions
How Big is the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?
The benign prostatic hyperplasia (BPH) prostate treatment market size is expected to be worth US$ 33,031.10 million in 2024.
How Big Will the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Be in 2034?
The benign prostatic hyperplasia (BPH) prostate treatment market is estimated to get as big as US$ 47,045.80 million in 2034.
How will the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Progress in the United States?
The CAGR of the benign prostatic hyperplasia (BPH) prostate treatment market during the 2024 to 2034 period in the United States is estimated to be 4.0%.
What are the Segments of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?
The benign prostatic hyperplasia (BPH) prostate treatment market can be divided into the following segments: treatment type and distribution channel.
What is the Scope of the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market?
The benign prostatic hyperplasia (BPH) prostate treatment market is expected to grow at a CAGR of 3.6% over the period from 2024 to 2034.
Who are the Key Players in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry?
Pfizer Inc., NxThera Inc., NeoTract Inc., and Sanofi S.A. are some of the key companies in the benign prostatic hyperplasia (BPH) prostate treatment Market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2024 to 2034
5.3.1. BPH Drugs
5.3.1.1. Alpha Blockers
5.3.1.2. 5-Aplha Reductase Inhibitors
5.3.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
5.3.1.4. Muscarinic Receptor Antagonist (MRA)
5.3.1.5. Combination Drug
5.3.2. BPH Devices
5.3.2.1. Prostatic Stents
5.3.2.2. Suture Base Implant Systems
5.3.2.3. Transurethral RF Thermal Therapy Devices
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034
6.3.1. Institutional Sales
6.3.1.1. Hospitals
6.3.1.2. Ambulatory Surgical Centres
6.3.1.3. Specialty Clinics
6.3.2. Retail Sales
6.3.2.1. Retail Pharmacies
6.3.2.2. Drug Stores
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Treatment Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Treatment Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Treatment Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Treatment Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Market Share Analysis, 2023
15.1.1.1. By Treatment Type
15.1.1.2. By Distribution Channel
15.2. Canada
15.2.1. Market Share Analysis, 2023
15.2.1.1. By Treatment Type
15.2.1.2. By Distribution Channel
15.3. Brazil
15.3.1. Market Share Analysis, 2023
15.3.1.1. By Treatment Type
15.3.1.2. By Distribution Channel
15.4. Mexico
15.4.1. Market Share Analysis, 2023
15.4.1.1. By Treatment Type
15.4.1.2. By Distribution Channel
15.5. Germany
15.5.1. Market Share Analysis, 2023
15.5.1.1. By Treatment Type
15.5.1.2. By Distribution Channel
15.6. UK
15.6.1. Market Share Analysis, 2023
15.6.1.1. By Treatment Type
15.6.1.2. By Distribution Channel
15.7. France
15.7.1. Market Share Analysis, 2023
15.7.1.1. By Treatment Type
15.7.1.2. By Distribution Channel
15.8. Spain
15.8.1. Market Share Analysis, 2023
15.8.1.1. By Treatment Type
15.8.1.2. By Distribution Channel
15.9. Italy
15.9.1. Market Share Analysis, 2023
15.9.1.1. By Treatment Type
15.9.1.2. By Distribution Channel
15.10. Poland
15.10.1. Market Share Analysis, 2023
15.10.1.1. By Treatment Type
15.10.1.2. By Distribution Channel
15.11. Russia
15.11.1. Market Share Analysis, 2023
15.11.1.1. By Treatment Type
15.11.1.2. By Distribution Channel
15.12. Czech Republic
15.12.1. Market Share Analysis, 2023
15.12.1.1. By Treatment Type
15.12.1.2. By Distribution Channel
15.13. Romania
15.13.1. Market Share Analysis, 2023
15.13.1.1. By Treatment Type
15.13.1.2. By Distribution Channel
15.14. India
15.14.1. Market Share Analysis, 2023
15.14.1.1. By Treatment Type
15.14.1.2. By Distribution Channel
15.15. Bangladesh
15.15.1. Market Share Analysis, 2023
15.15.1.1. By Treatment Type
15.15.1.2. By Distribution Channel
15.16. Australia
15.16.1. Market Share Analysis, 2023
15.16.1.1. By Treatment Type
15.16.1.2. By Distribution Channel
15.17. New Zealand
15.17.1. Market Share Analysis, 2023
15.17.1.1. By Treatment Type
15.17.1.2. By Distribution Channel
15.18. China
15.18.1. Market Share Analysis, 2023
15.18.1.1. By Treatment Type
15.18.1.2. By Distribution Channel
15.19. Japan
15.19.1. Market Share Analysis, 2023
15.19.1.1. By Treatment Type
15.19.1.2. By Distribution Channel
15.20. South Korea
15.20.1. Market Share Analysis, 2023
15.20.1.1. By Treatment Type
15.20.1.2. By Distribution Channel
15.21. GCC Countries
15.21.1. Market Share Analysis, 2023
15.21.1.1. By Treatment Type
15.21.1.2. By Distribution Channel
15.22. South Africa
15.22.1. Market Share Analysis, 2023
15.22.1.1. By Treatment Type
15.22.1.2. By Distribution Channel
15.23. Israel
15.23.1. Market Share Analysis, 2023
15.23.1.1. By Treatment Type
15.23.1.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Pfizer Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. NxThera Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. NeoTract Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Sanofi S.A
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. GlaxoSmithKline Plc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Allergan Plc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Teva Pharmaceutical Industries Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Mylan N.V.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Eli Lily & Company
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Cardinal Health Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 11: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 20: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness by Treatment Type, 2024 to 2034
Figure 14: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 15: Global Market Attractiveness by Region, 2024 to 2034
Figure 16: North America Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 28: North America Market Attractiveness by Treatment Type, 2024 to 2034
Figure 29: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 30: North America Market Attractiveness by Country, 2024 to 2034
Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 43: Latin America Market Attractiveness by Treatment Type, 2024 to 2034
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 46: Western Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 52: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 58: Western Europe Market Attractiveness by Treatment Type, 2024 to 2034
Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 61: Eastern Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 73: Eastern Europe Market Attractiveness by Treatment Type, 2024 to 2034
Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 76: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 88: South Asia and Pacific Market Attractiveness by Treatment Type, 2024 to 2034
Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 91: East Asia Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 97: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 103: East Asia Market Attractiveness by Treatment Type, 2024 to 2034
Figure 104: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 106: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2024 to 2034
Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 118: Middle East and Africa Market Attractiveness by Treatment Type, 2024 to 2034
Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
